Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good and Poor Responders to Radiotherapy: A Rectal Cancer Multicentre Randomised Control Trial to Avoid Surgery With 'Watch and Wait' or Intensify Treatment According to mrTRG

NCT02704520 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT02704520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02704520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker to Stratify Management of Good and Poor Responders to Radiotherapy: A Rectal Cancer Multicentre Randomised Control Trial to Avoid Surgery With 'Watch and Wait' or Intensify Treatment According to mrTRG
Lead sponsor
Imperial College London
Phase
Not applicable
Overall status
Recruiting
Start date
March 31, 2016
Completion date
December 31, 2036
Enrollment
441 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer